This is the first meta-analysis on the combined OS/PFS of WBRT plus EGFR-TKIs versus WBRT alone and EGFR-TKIs alone for NSCLC patients with multiple BM. This evidence concerns the gene EGFR and non-small cell lung carcinoma.